Sunshine Biopharma Inc (SBFM) News

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements

Form 8-K - Current report

Form DEF 14A - Other definitive proxy statements

Form PRE 14A - Other preliminary proxy statements

Form 8-K - Current report

Sunshine Biopharma Reports 2023 Second Quarter Results: Revenues Up 3,600%

MONTREAL, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”) (the “Company”), a...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Notice of Effectiveness (effect)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 NOTICE OF EFFECTIVENESSEffective Date:June 05, 2023 4:30...

Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)

Table of Contents   Filed pursuant to Rule 424(b)(3) Under the Securities Act of 1933, as amended Registration No...

Securities Registration Statement (simplified Form) (s-3)

Table of Contents As filed with the Securities and Exchange Commission on May 25, 2023   Registration No...

Small Company Offering and Sale of Securities Without Registration (d)

 UNITED STATES SECURITIESAND EXCHANGE COMMISSIONWashington, D.C.FORM DOMB APPROVALOMB Number: 3235-0076Estimated Average burden hours per...

Sunshine Biopharma Announces Closing of $5.0 Million Private Placement Priced At-the-Market

MONTREAL, May 16, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company...

Sunshine Biopharma Announces Pricing of $5.0 Million Private Placement Priced At-the-Market

MONTREAL, May 12, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company...

Current Report Filing (8-k)

0001402328 false 0001402328 2023-05-11 2023-05-11 0001402328...